This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina (ILMN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $328.96, moving +0.73% from the previous trading session.
Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.
Illumina (ILMN) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $307.45, moving +0.88% from the previous trading session.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Why Illumina (ILMN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce
by Zacks Equity Research
Insmed's (INSM) lung infection drug Arikayce gains an accelerated approval from the FDA for the treatment of lung disease caused by mycobacterium avium complex (MAC).
Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM
by Zacks Equity Research
Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM
Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Looking for Earnings Beat? Play These Top 5 Stocks
by Sanghamitra Saha
These top-ranked stocks may surpass bottom-line estimates in their next release.
Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Atara Biotherapeutics (ATRA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Alexion's Soliris Successful in Phase III Study for NMOSD
by Zacks Equity Research
Alexion's (ALXN) efforts to expand lead blockbuster drug Soliris' label gets a boost as the phase III study on the drug for the indication of NMSOD was successful.
AnaptysBio (ANAB) Looks Good: Stock Adds 9.9% in Session
by Zacks Equity Research
AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Is First Trust Multi Cap Growth AlphaDEX Fund (FAD) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
Major Stock Indexes Approaching Record Highs: 5 Top Picks
by Nalak Das
The three major stock market indexes ??? the Dow 30, S&P 500 and Nasdaq Composite ??? are at present within the striking distance to achieve their all-time high level.
Cytori's Chemotherapy Candidate Gets Orphan Drug Status
by Zacks Equity Research
Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.
AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
DENTSPLY Launches Azento, Improves Digital Implant Workflow
by Zacks Equity Research
DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.
IPOs and Foreign Investment Propel Biotech: 4 Top Picks
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.
Allscripts' Sunrise Abstracting Selected by Wyckoff Heights
by Nabaparna Bhattacharya
Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.
Is Illumina (ILMN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Sweta Killa
Sector ETF report for ARKG
Here's Why You Should Hold On to DaVita (DVA) Stock Now
by Zacks Equity Research
Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.
Thermo Fisher to Acquire BD's Advanced Bioprocessing Unit
by Zacks Equity Research
BD's (BDX) Advanced Bioprocessing business generates revenues worth $100 million annually. The unit will be integrated in the Thermo Fisher's (TMO) Life Sciences Solutions Segment.